Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes

被引:1
|
作者
Medina, Miguel [1 ]
Avila, Jesus [1 ,2 ]
机构
[1] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid 28041, Spain
[2] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid 28049, Spain
关键词
Alzheimer's; dementia; GSK-3; long-term depression; long-term potentiation; memory; neurodegeneration; synaptic plasticity; GLYCOGEN-SYNTHASE KINASE-3; BETA PRECURSOR PROTEIN; LONG-TERM POTENTIATION; TAU-PROTEIN; IN-VIVO; TRANSGENIC MICE; AMYLOID PATHOLOGY; NEURONAL POLARITY; SIGNALING PATHWAY; EXTRACELLULAR TAU;
D O I
10.1586/ERN.13.39
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Originally discovered because of its role in the regulation of glucose metabolism, GSK-3 is now widely recognized as a crucial player in many cellular functions. Control of GSK-3 activity occurs by complex mechanisms that are each dependent upon specific signaling pathways. Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder. In this article, the authors will specifically focus on the role of this enzyme as a key regulator of synaptic plasticity and how alterations in the GSK-3 synaptic functions may be a major factor in AD and other neurodegenerative disorders.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 50 条
  • [1] The role of GSK-3 in synaptic plasticity
    Peineau, S.
    Bradley, C.
    Taghibiglou, C.
    Doherty, A.
    Bortolotto, Z. A.
    Wang, Y. T.
    Collingridge, G. L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 : S428 - S437
  • [2] A pivotal role of GSK-3 in synaptic plasticity
    Bradley, Clarrisa A.
    Peineau, Stephane
    Taghibiglou, Changiz
    Nicolas, Celine S.
    Whitcomb, Daniel J.
    Bortolotto, Zuner A.
    Kaang, Bong-Kiun
    Cho, Kwangwook
    Wang, Yu Tian
    Collingridge, Graham L.
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2012, 5
  • [3] GSK-3 is essential in the pathogenesis of Alzheimer's disease
    Takashima, Akihiko
    JOURNAL OF ALZHEIMERS DISEASE, 2006, 9 : 309 - 317
  • [4] GSK-3:: Its role in τ phosphorylation and synaptic plasticity
    Lovestone, S
    Chee, F
    Killick, R
    MacKay, D
    Markevich, V
    Mudher, A
    Shepherd, D
    Stephenson, J
    NEUROBIOLOGY OF AGING, 2004, 25 : S8 - S8
  • [5] Role of GSK-3β in Alzheimer's disease pathology
    Planel, E
    Sun, XY
    Takashima, A
    DRUG DEVELOPMENT RESEARCH, 2002, 56 (03) : 491 - 510
  • [6] GSK-3β, a pivotal kinase in Alzheimer disease
    Llorens-Martin, Maria
    Jurado, Jeronimo
    Hernandez, Felix
    Avila, Jesus
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2014, 7
  • [7] GSK-3 in Huntington's disease
    Eldar-Finkelman, Hagit
    Rippin, Ido
    Ruiz, Sara Melisa Arciniegas
    JOURNAL OF NEUROCHEMISTRY, 2022, 162 : 69 - 70
  • [8] GSK-3 and Tau: A Key Duet in Alzheimer's Disease
    Sayas, Carmen Laura
    Avila, Jesus
    CELLS, 2021, 10 (04)
  • [9] GSK-3 inhibitors and their potential in the treatment of Alzheimer's disease
    Kypta, RM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (10) : 1315 - 1331
  • [10] β-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease
    Preece, P
    Virley, DJ
    Costandi, M
    Coombes, R
    Moss, SJ
    Mudge, AW
    Jazin, E
    Cairns, NJ
    MOLECULAR BRAIN RESEARCH, 2003, 116 (1-2): : 155 - 158